Evaluation of the Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Statin Intolerant Patients of an Outpatient Lipid Clinic
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI